You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
AML1-ETO Fusion Protein up-Regulates TRKA mRNA Expression in Human CD34+ Cells, Allowing Nerve Growth Factor-Induced Expansion
James C. Mulloy, Vladimir Jankovic, Mark Wunderlich, Ruud Delwel, Jorg Cammenga, Ondrej Krejci, Hui Zhao, Peter J. M. Valk, Bob Lowenberg, Stephen D. Nimer and Janet D. Rowley
Proceedings of the National Academy of Sciences of the United States of America
Vol. 102, No. 11 (Mar. 15, 2005), pp. 4016-4021
Published by: National Academy of Sciences
Stable URL: http://www.jstor.org/stable/3374858
Page Count: 6
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
The AML1-ETO fusion protein, generated by the t(8;21) in acute myeloid leukemia (AML), exerts dominant-negative functions and a variety of gains of function, including a positive effect on the growth of primary human CD34+ hematopoietic stem/progenitor cells. We now show that AML1-ETO expression up-regulates the level of TRKA mRNA and protein in these cells and that AML1-ETO-expressing CD34+ hematopoietic cells grown in the presence of five early-acting hematopoietic cytokines further proliferate in response to nerve growth factor (NGF). These cells also show a unique response to NGF and IL-3; namely, they expand in liquid culture. To determine the biological relevance of our findings, we analyzed 262 primary AML patient samples using real-time RT-PCR and found that t(8;21)-positive AML samples express significantly higher levels of TRKA mRNA than other subtypes of AML. NGF, which is normally expressed by bone marrow stromal cells, could provide important proliferative or survival signals to AML1-ETO-expressing leukemic or preleukemic cells, and the NGF/TRKA signaling pathway may be a suitable target for therapeutic approaches to AML.
Proceedings of the National Academy of Sciences of the United States of America © 2005 National Academy of Sciences